Derived From Animal Tissue (e.g., Rennin, Etc.) Patents (Class 435/226)
  • Patent number: 10306873
    Abstract: The present invention relates to expression cassettes and vectors comprising Alzheimer's disease-related genes and a cell line transformed by the disclosed expression cassettes and vectors, and more specifically, the expression cassettes according to the present invention comprise amyloid precursor protein (APP), Tau protein, and presenilin-1 (PS1) genes associated with Alzheimer's disease so that mutant genes thereof can be simultaneously expressed. Additionally, the present invention relates to a cell line transformed by the disclosed expression cassettes or vectors comprising APP, Tau protein, and PS1 genes, and further, to an animal model transformed by the vectors or cell line.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: June 4, 2019
    Assignee: Jeju National University Industry-Academic Cooperation Foundation
    Inventors: Se Pill Park, Young Sok Choi, Eun Young Kim, Young Ho Kim, Hyun Seok Hong, Chan Kyu Park, Mi Seon Park
  • Patent number: 10272142
    Abstract: Compositions and methods useful for the treatment of neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD) are disclosed.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: April 30, 2019
    Assignee: SHIRE VIROPHARMA INCORPORATED
    Inventors: Colin Broom, Jeffrey Dayno
  • Patent number: 10232023
    Abstract: An isolated and purified peptide, neonatal NET-inhibitory Factor (nNIF), is disclosed. Methods for treatment of and prophylaxis against inflammatory disorders are also disclosed, including methods of treatment of and prophylaxis against inflammatory disorders comprising administering NET-inhibitory peptides (NIPs), which may be a nNIF, a pharmaceutically acceptable salt of a nNIF, a nNIF analog, a pharmaceutically acceptable salt of a nNIF analog, a nNIF-Related Peptide (nNRP), including the nNRP, Cancer-Associated SCM-Recognition, Immune Defense Suppression, and Serine Protease Protection Peptide (CRISPP), a pharmaceutically acceptable salt of a nNRP, a nNRP analog, or a pharmaceutically acceptable salt of a nNRP analog, to an individual.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: March 19, 2019
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Christian Con Yost, Guy A. Zimmerman, Andrew S. Weyrich
  • Patent number: 10167448
    Abstract: The present invention relates to a pharmaceutical composition for treating cerebrovascular diseases including stem cell-derived exosomes as an active ingredient. The stem cell-derived exosomes according to the present invention have superior nerve cell protective effects, such as inhibition of cerebral ventricular distention, reduction of hydrocephalus, and inhibition of nerve cell death and cellular inflammation in an intraventricular hemorrhage (IVH) animal model, and thus, can be useful in treating cerebrovascular diseases including intraventricular hemorrhage, etc.
    Type: Grant
    Filed: December 12, 2014
    Date of Patent: January 1, 2019
    Assignee: Samsung Life Public Welfare Foundation
    Inventors: Yun Sil Chang, Won Soon Park, Dong Kyung Sung, So Yoon Ahn
  • Patent number: 10070631
    Abstract: Genetically modified rodents such as mice and rats, and methods and compositions for making and using the same, are provided. The rodents comprise a humanization of at least one endogenous rodent Tmprss gene, such as an endogenous rodent Tmprss2, Tmprss4, or Tmprss11d gene.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: September 11, 2018
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Lisa Purcell, Alexander O. Mujica, Yajun Tang
  • Patent number: 10070632
    Abstract: Genetically modified rodents such as mice and rats, and methods and compositions for making and using the same, are provided. The rodents comprise a humanization of at least one endogenous rodent Tmprss gene, such as an endogenous rodent Tmprss2, Tmprss4, or Tmprss11d gene.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: September 11, 2018
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventors: Lisa Purcell, Alexander O. Mujica, Yajun Tang
  • Patent number: 9982021
    Abstract: The present invention relates to: a composition for dissolving thrombi comprising a peptide comprising the Arg-Gly-Asp motif; a pharmaceutical composition for treating stenotic or occlusive vascular diseases which comprises the same; and a thrombus dissolving method and a method for treating stenotic or occlusive vascular diseases, comprising the step of administering the same. The compositions and methods of the present invention have the advantage that they effectively break down already formed thrombi by adopting the principle of targeting integrin within the thrombus such as platelet surface GPIIb-IIIa, which is not the same as the existing principle of plasminogen activation. Also, the compositions and methods of the present invention have a nerve-protecting function as they effectively open as far as the microvasculature, without the occurrence of restenosis after penetration.
    Type: Grant
    Filed: November 1, 2011
    Date of Patent: May 29, 2018
    Assignee: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY
    Inventors: Ji Hoe Heo, Il Kwon, Young Dae Kim, Sung Yu Hong
  • Patent number: 9982248
    Abstract: Disclosed are a modified FIX (factor IX) polypeptide comprising a leucine, cysteine, aspartic acid, glutamic acid, histidine, lysine, asparagine, glutamine or tyrosine in position 338; pharmaceutical preparations containing said modified FIX polypeptide; a nucleotide sequence coding for the modified FIX polypeptide; and a method for producing the modified FIX polypeptide.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: May 29, 2018
    Assignee: UNIQURE BIOPHARMA B.V.
    Inventor: Paolo Simioni
  • Patent number: 9950043
    Abstract: Modulation of the ADAMTS1 signaling pathway alters the commitment of progenitor cells to a muscle fate; and increases muscle mass.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: April 24, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventor: Brian Jay Feldman
  • Patent number: 9951337
    Abstract: The invention relates to the field of medicinal research, cartilage physiology and diseases involving the degeneration of cartilage tissue. More specifically, the invention relates to methods and means for identifying compounds that inhibit catabolic processes in chondrocytes and that decrease the degradation of cartilage and/or ECM. The invention also relates to the compounds that are useful in the treatment of osteoarthritis. The invention also relates to targets, the modulation of which results in a decrease in the degradation of ECM and/or cartilage and decrease inflammation. In addition, the invention relates to compositions and methods for the use thereof in treating conditions that are characterized by the degradation of ECM and/or cartilage and inflammation.
    Type: Grant
    Filed: February 3, 2016
    Date of Patent: April 24, 2018
    Assignee: GALAPAGOS NV
    Inventors: Reginald Christophe Xavier Brys, Luc Nelles, Nick Ernest Rene Vandeghinste, Blandine Mille-Baker, Michela Angela Tessari
  • Patent number: 9920109
    Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing and purifying such molecules.
    Type: Grant
    Filed: August 19, 2013
    Date of Patent: March 20, 2018
    Assignee: Inhibrx LP
    Inventors: Brendan Eckelman, John Timmer, Quinn Deveraux
  • Patent number: 9657337
    Abstract: Embodiments of the present invention relate to a buffer composition for an integrated nucleic acid amplification and hybridization reaction. The buffer comprise about 50-200 mM of a salt, about 10-30 mM Tris-HCl, about 2-10M Water soluble magnesium salt, about 0.05-1.5% surfactant, about 0.05-0.15 mg/ml stabilizing protein about 50-300 nM of one or more primers, about 20-150 uM of one or more dNTPs, about 5-15% glycerine, about 0.5-1.5% formamide and at least about 5 unit/ml polymerase.
    Type: Grant
    Filed: December 29, 2006
    Date of Patent: May 23, 2017
    Assignee: Honeywell International Inc.
    Inventors: Leon Xu, Zhenhong Sun
  • Patent number: 9539315
    Abstract: Screening assays and methods of using same for screening to identify modulator agents or compounds that affect matrix metalloproteinase-2 (MMP-2) mediated activation of toll-like receptor-2 (TLR-2) are described herein. Pharmaceutical and immunogenic compositions comprising agents or compounds that modulate MMP-2 mediated activation of TLR-2 are also encompassed. Methods for modulating MMP-2 mediated activation of TLR-2 using MMP-2 peptides in pharmaceutical and immunogenic compositions, as well as vaccines, are also envisioned. Melanoma is an exemplary tumor type that expresses MMP-2 and for which such pharmaceutical and immunogenic compositions, as well as vaccines, would confer benefit to patients. Also encompassed are methods for reducing MMP-2 mediated activation of TLR-2 and downstream signaling therefrom so as to achieve more effective T cell responses to MMP-2 expressing tumors.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: January 10, 2017
    Assignee: New York University
    Inventors: Emmanuelle Godefroy, Nina Bhardwaj
  • Patent number: 9499606
    Abstract: A novel method of treating and preventing bacterial diseases is provided. In particular, the present invention relates to compositions and methods for inhibition of Gram negative, Gram positive and acid fast bacilli in general and tuberculosis (TB), mycobacterium avium complex (MAC), and anthrax in particular. Thus, the invention relates to modulation of cellular activities, including macrophage activity, and the like. More particularly, the present invention relates to the inhibitory compounds comprising naturally occurring and man-made inhibitors of serine protease.
    Type: Grant
    Filed: August 2, 2013
    Date of Patent: November 22, 2016
    Assignee: The Regents of the University of Colorado, a body corporate
    Inventor: Leland Shapiro
  • Patent number: 9249406
    Abstract: The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases.
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: February 2, 2016
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Caen Basse Normandie
    Inventors: Denis Vivien, Jerome Parcq
  • Patent number: 9169519
    Abstract: Disclosed herein are methods relating to inhibiting or reducing proliferation of a cancer cell, for treating cancer in a subject in need of treatment, predicting the risk of progression of cancer to a more aggressive cancer, and screening for cancer in a subject, that comprise detecting and/or decreasing the levels of SUMO conjugated proteins and detecting and/or interfering with SUMO conjugation.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: October 27, 2015
    Assignee: Duke University
    Inventors: Wulf Paschen, Wei Yang, Huaxin Sheng, David S. Warner
  • Patent number: 9150659
    Abstract: Anti-TACE (ADAM17) antibodies are disclosed that for the first time in the art are capable of binding to TACE, of acting as antagonists of one or more its biological activities, in particular by binding to TACE in a cross domain binding mode in which residues in both the catalytic domain and in the cysteine rich/disintegrin domains (Dis-Cys) are involved in antibody binding to TACE, helping to improve the specificity of the antibody binding and/or helping to improve inhibition of TACE biological activity. The therapeutic uses of the antibodies, in particular for the treatment of cancer are disclosed.
    Type: Grant
    Filed: January 30, 2012
    Date of Patent: October 6, 2015
    Inventors: Gillian Murphy, Christopher Tape, John McCafferty
  • Patent number: 9150844
    Abstract: The present invention discloses novel hybrid proteins that have both plasminogen activator and anti-thrombotic properties, including clot specific action, that renders these as highly advantageous for the treatment of circulatory disorders involving fibrin clot formation due to underlying tissue damage in the blood vessels leading to myocardial infarction, strokes etc. Also disclosed are new proteins, and methods of obtaining the same, that help to dissolve blood clots by activating plasminogen in a plasmin or thrombin dependent manner and also inhibit both the activity and generation of thrombin through the intrinsic pathway of blood coagulation.
    Type: Grant
    Filed: August 5, 2011
    Date of Patent: October 6, 2015
    Inventors: Neeraj Maheshwari, Girish Sahni
  • Patent number: 9109011
    Abstract: The present invention includes compositions and methods for making and using a vaccine that includes a DC-specific antibody or fragment thereof to which an engineered Gag antigen is attached to form an antibody-antigen complex, wherein the Gag antigen is less susceptible to proteolytic degradation by eliminating one or more proteolytic sites or a DC-specific antibody or fragment thereof to which an engineered Nef antigen is attached to form an antibody-antigen complex, wherein the Nef antigen comprises one or more codon usage optimization that increase antibody-antigen complex secretion, or both, wherein the vaccine is able to elicit an HIV-specific T cell immune response to Gag p17, Gag p24, Nef and/or Cyclin D1.
    Type: Grant
    Filed: July 16, 2009
    Date of Patent: August 18, 2015
    Assignee: Baylor Research Institute
    Inventors: Jacques F. Banchereau, Gerard Zurawski, Anne-Laure Flamar, Amanda Cobb, Holly Mead, Monica Montes, Sandra Zurawski, SangKon Oh
  • Publication number: 20150147308
    Abstract: Described herein are compositions which include digestive enzymes and which are formulated to reduce one or more symptoms of a neuropsychiatric disorder. Also described herein is a method for treating an individual with a neuropsychiatric disorder using digestive enzymes and their derivatives to alleviate the symptoms of neuropsychiatric disorders. The method comprises administering to the individual an effective amount of digestive enzymes that are either naturally or recombinantly derived, or their derivatives, in an amount effective to reduce one or more symptoms of the neuropsychiatric disorder.
    Type: Application
    Filed: February 3, 2015
    Publication date: May 28, 2015
    Inventors: Joan M. Fallon, Matthew Heil, James Szigethy, James Fallon
  • Publication number: 20150140169
    Abstract: The invention relates to a polypeptide having chymosin activity which: a. is capable of hydrolysing bovine alpha s1-casein at position F23F24 so as to form ?s1-I CN (f24-199) more rapidly than camel chymosin; and b. has a C/P ratio higher than the C/P ratio of bovine chymosin.
    Type: Application
    Filed: May 3, 2013
    Publication date: May 21, 2015
    Inventors: Petrus Jacobus Theodorus Dekker, René Marcel De Jong, Michael Dennis Tabeling, Cornelis Marinus Muijlwijk
  • Publication number: 20150133531
    Abstract: The present invention provides a method of expressing at least one heterologous nucleic acid sequence in a cell, the method comprising introducing at least one heterologous nucleic acid sequence into a cell by infecting said cell with a recombinant negative-strand RNA virus vector comprising said at least one heterologous nucleic acid sequence, wherein the recombinant negative-strand RNA virus vector includes a viral genome coding for a mutated P protein, which leads to a loss of the viral genome replication ability without a loss of the viral transcription ability, and wherein said at least one heterologous nucleic acid sequence encodes a cellular reprogramming or programming factor or a therapeutic protein. In addition, the present invention provides a cell or a population of cells prepared in vitro by said method as well as a pharmaceutical composition comprising said cell or population of cells.
    Type: Application
    Filed: May 24, 2013
    Publication date: May 14, 2015
    Applicant: AmVac AG
    Inventor: Marian Wiegand
  • Publication number: 20150132770
    Abstract: The present invention provides pregnancy associated plasma protein A2 (PAPP-A2), its nucleotide and amino acid sequences, antisense molecules to the nucleotide sequences which encode PAPP-A2, expression vectors for the production of purified PAPP-A2, antibodies capable of binding specifically to PAPP-A2, hybridization probes or oligonucleotides for the detection of PAPP-A2-encoding nucleotide sequences, genetically engineered host cells for the expression of PAPP-A2, and methods for screening for pathologies in pregnant and non-pregnant patients. Methods for screening for altered focal proliferation states in pregnant and/or non-pregnant patients, which include detecting levels of PAPP-A2, are also described.
    Type: Application
    Filed: August 22, 2014
    Publication date: May 14, 2015
    Inventors: Claus Oxvig, Michael Toft Overgaard
  • Publication number: 20150132826
    Abstract: The present invention discloses a thrombolytic therapy for acute myocardial infarction by t-PA. A chimeric truncated form of t-PA is designed and expressed in Pichia pastoris. The new variant t-PA comprises of a finger domain of Desmoteplase, an epidermal growth factor (EGF) domain, a kringle 1 domain, a kringle 2 domain in which the lysine binging site is deleted, and a protease domain where the four amino acids lysine 296, arginine 298, arginine 299, and arginine 304 are substituted by aspartic acid. The chimeric t-PA shows has increased activity of 14 fold in presence of fibrin. The t-PA shows 10-fold increased potency than commercially available full length t-PA (Actylase®) and provides 1.2 fold greater affinity to fibrin. Further a residual activity of only 68% is observed after incubation of Actylase® with PAI-1 and 91% residual activity for t-PA. The t-PA variant is acceptable plasminogen activator with enhanced biochemical properties.
    Type: Application
    Filed: January 11, 2015
    Publication date: May 14, 2015
    Inventors: Amirhossein Saadatirad, Fereidoun Mahboudi, Soroush Sardari, Mohammadreza Kazemali, Fatemeh Davami, Keyvan Majidzadeh
  • Publication number: 20150104849
    Abstract: Provided herein are methods for purifying recombinant A Disintegrin-like and Metallopeptidase with Thrombospondin Type 1 Motif 13 (ADAMTS13) protein from a sample. The method comprises enriching for ADAMTS13 protein by chromatographically contacting the sample with hydroxyapatite under conditions that allow ADAMTS13 protein to appear in the eluate or supernatant from the hydroxylapatite. The methods may further comprise tandem chromatography with a mixed mode cation exchange/hydrophobic interaction resin that binds ADAMTS13 protein. Additional optional steps involve ultrafiltration/diafiltration, anion exchange chromatography, cation exchange chromatography, and viral inactivation. Also provided herein are methods for inactivating virus contaminants in protein samples, where the protein is immobilized on a support. Also provided herein are compositions of ADAMTS13 prepared according to said methods.
    Type: Application
    Filed: December 16, 2014
    Publication date: April 16, 2015
    Inventors: Meinhard Hasslacher, Christian Fiedler, Christa Mayer, Artur Mitterer
  • Patent number: 9005949
    Abstract: The present invention provides pregnancy associated plasma protein A2 (PAPP-A2), its nucleotide and amino acid sequences, antisense molecules to the nucleotide sequences which encode PAPP-A2, expression vectors for the production of purified PAPP-A2, antibodies capable of binding specifically to PAPP-A2, hybridization probes or oligonucleotides for the detection of PAPP-A2-encoding nucleotide sequences, genetically engineered host cells for the expression of PAPP-A2, and methods for screening for pathologies in pregnant and non-pregnant patients. Methods for screening for altered focal proliferation states in pregnant and/or non-pregnant patients, which include detecting levels of PAPP-A2, are also described.
    Type: Grant
    Filed: September 24, 2012
    Date of Patent: April 14, 2015
    Assignee: Como Biotech ApS
    Inventors: Claus Oxvig, Michael Toft Overgaard
  • Publication number: 20150086524
    Abstract: Methods and dosage formulations are provided for subcutaneous administration in which therapeutic agents are modified to increase the hydrophilicity and molecular dimensions in relation to the native state of the therapeutic agent, in which the Cmax:Caverage ratio is lower than the Cmax:Caverage ratio of the agent when delivered intravenously.
    Type: Application
    Filed: April 16, 2013
    Publication date: March 26, 2015
    Applicant: CANTAB BIOPHARMACEUTICALS PATENTS LIMITED
    Inventors: William Henry, Richard Wolf-Garraway, John Charles Mayo, Michael James Earl
  • Publication number: 20150079063
    Abstract: Polypeptides comprising at least one carboxy-terminal peptide (CTP) of chorionic gonadotropin attached to the carboxy terminus but not to the amino terminus of a coagulation factor and polynucleotides encoding the same are disclosed. Pharmaceutical compositions comprising the polypeptides and polynucleotides of the invention and methods of using and producing same are also disclosed.
    Type: Application
    Filed: May 9, 2014
    Publication date: March 19, 2015
    Applicant: OPKO Biologics Ltd.
    Inventors: Udi Eyal FIMA, Gili Hart
  • Publication number: 20150064744
    Abstract: The present invention is related to novel mammalian enterokinase analogues such as mammalian enterokinase light chain analogues and methods of making such. Also described herein is a method for cleaving proteins having an enterokinase cleavage site.
    Type: Application
    Filed: December 20, 2012
    Publication date: March 5, 2015
    Inventors: Helle Fabricius Woeldicke, Xujia Zhang, Yun Liu, Weiwei Tong
  • Publication number: 20150064236
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
    Type: Application
    Filed: March 9, 2013
    Publication date: March 5, 2015
    Inventors: Stephane Bancel, Tirtha Chakraborty, Antonin de Fougerolles, Sayda M. Elbashir, Matthias John, Atanu Roy, Susan Whoriskey, Kristy M. Wood, Paul Hatala, Jason P. Schrum, Kenechi Ejebe, Jeff Lynn Ellsworth, Justin Guild
  • Publication number: 20150056657
    Abstract: Among other aspects, the present invention relates to cell culture conditions for producing high molecular weight vWF, in particular, highly multimericWF with a high specific activity and ADAMTS13 with a high specific activity. The cell culture conditions of the present invention can include, for example, a cell culture medium with an increased copper concentration and/or cell culture supernatant with a low ammonium (NH4+) concentration. The present invention also provides methods for cultivating cells in the cell culture conditions to express high molecular weight vWF and rA13 having high specific activities.
    Type: Application
    Filed: September 3, 2014
    Publication date: February 26, 2015
    Inventors: Leopold Grillberger, Manfred Reiter, Wolfgang Mundt, Daniel Fleischanderl, Gregor Bramberger
  • Publication number: 20150050264
    Abstract: The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases.
    Type: Application
    Filed: September 7, 2012
    Publication date: February 19, 2015
    Applicant: Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Denis VIVIEN, Jerome PARCQ, Denis VIVIEN, Jerome PARCQ
  • Publication number: 20150050278
    Abstract: Fc domains and CH3 domains are disclosed that bind the neonatal Fc (FcRn) receptor and are at least 99% monomeric. Monomeric Fc domain molecules and CH3 domain molecules are disclosed herein that include a monomeric Fc domain or a monomeric CH3 domain and an effector molecule. In some embodiments, the monomeric Fc or monomeric CH3 domain include amino acid substitutions and/or CDR insertions in the beta strands such that they specifically bind an antigen. Methods for using these monomeric Fc domains, monomeric CH3 domains, monomeric Fc domain molecules and CH3 domain molecules are also provided.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 19, 2015
    Inventors: Dimiter S. Dimitrov, Tianlei Ying
  • Publication number: 20150050716
    Abstract: An enhanced disintegrin-like domain, and metalloprotease, with an isolated human thrombospondin type 1 motif, member 13 (ADAMTS-13) that includes substitutions at one or more positions in the isolated human ADAMTS-13.
    Type: Application
    Filed: October 30, 2014
    Publication date: February 19, 2015
    Applicant: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
    Inventor: Kenji SOEJIMA
  • Patent number: 8956848
    Abstract: A UBP1 protease mutant and the sequence coding it, their application and products and the methods used to produce them may be used in the production of recombinant proteins, particularly on an industrial scale.
    Type: Grant
    Filed: November 1, 2005
    Date of Patent: February 17, 2015
    Assignee: Instytut Biotechnoloii I Antybiotykow
    Inventors: Andrzej Plucienniczak, Anna Wojtowicz, Diana Mikiewicz-Sygula, Grazyna Plucienniczak
  • Publication number: 20150044171
    Abstract: Compositions and methods for the treatment of thrombotic thrombocytopenic purpura are disclosed.
    Type: Application
    Filed: June 23, 2014
    Publication date: February 12, 2015
    Inventor: X. Long Zheng
  • Publication number: 20150044207
    Abstract: The Invention relates to a chimeric protein comprising at least one clotting factor and at least a portion of an immunoglobulin constant region. The invention relates to a method of treating a hemostatic disorder comprising administering a therapeutically effective amount of a chimeric protein wherein the chimeric protein comprises at least one clotting factor and at least a portion of an immunoglobulin constant region.
    Type: Application
    Filed: July 17, 2014
    Publication date: February 12, 2015
    Applicant: Biogen Idec Hemophilia Inc.
    Inventors: Daniel S. RIVERA, Robert T. Peters, Alan J. Bitonti
  • Publication number: 20150044720
    Abstract: The present invention relates to an improved method for the serum-free production of an immortalized human cell line stably transfected under serum-free conditions with a specific vector carrying the gene coding for the protein of interest. Furthermore the invention relates to a production cell line obtained by said method, a production method for said protein of interest utilizing said production cell line, and the specific vector carrying the gene of interest itself.
    Type: Application
    Filed: October 3, 2014
    Publication date: February 12, 2015
    Applicant: Octapharma AG
    Inventors: Carola Schroeder, Haiyan Ding, Cathleen Wegmann
  • Publication number: 20150037842
    Abstract: The disclosure relates to a Gram negative bacterial cell that is transformed with a nucleic acid molecule that encodes a Gram positive twin-arginine translocase and including methods for the production of polypeptides.
    Type: Application
    Filed: February 22, 2013
    Publication date: February 5, 2015
    Inventor: Colin Robinson
  • Publication number: 20150023947
    Abstract: A virally safe, thrombin-free factor-XIa concentrate or a coagulation factor concentrate which contains factor XIa as an active pharmaceutical ingredient and which is obtained by fractionation of plasma or serum or by genetic engineering and is suitable for the treatment of coagulation disorders attributable to diminished and/or delayed thrombin formation.
    Type: Application
    Filed: July 21, 2014
    Publication date: January 22, 2015
    Inventor: Johann EIBL
  • Publication number: 20150023944
    Abstract: A method for treating a Parkinson's patient with digestive/pancreatic enzymes involves administering an effective amount of digestive/pancreatic enzymes to an individual having the disorder in order to improve a symptom of the disorder. In addition, a method is provided for determining whether an individual has, or may develop, Parkinson's disease or related dysautonomic disorders and for determining whether an individual will benefit from the administration of pancreatic/digestive enzymes to treat the dysautonomic disorder.
    Type: Application
    Filed: September 23, 2014
    Publication date: January 22, 2015
    Inventor: Joan M. Fallon
  • Publication number: 20150017685
    Abstract: The present invention relates to processes for the production of peptides, and the peptides produced accordingly. Peptides produced according to the invention may be produced more efficiently than peptides produced according to prior art processes. The production process of the invention may lead to advantages in yield, purity, and/or price. Methods of marketing peptides are also disclosed.
    Type: Application
    Filed: July 8, 2014
    Publication date: January 15, 2015
    Inventors: Michael H. B. Stowell, Jonathan Caruthers, Travis Nemkov, Brian Hiester, Leslie Boux, Mikhail Plam
  • Publication number: 20150010556
    Abstract: Cell-targeted serine protease constructs are provided. Such constructs can be used in methods for targeted cell killing such as for treatment cell of proliferative diseases (e.g., cancer). In some aspects, recombinant serine proteases, such as Granzyme B polypeptides, are provided that exhibit improved stability and cell toxicity. Methods and compositions for treating lapatinib or trastuzumab-resistant cancers are also provided.
    Type: Application
    Filed: July 2, 2014
    Publication date: January 8, 2015
    Applicant: RESEARCH DEVELOPMENT FOUNDATION
    Inventors: Michael G. ROSENBLUM, Khalid Amanali MOHAMEDALI, Lawrence H. CHEUNG
  • Publication number: 20140369992
    Abstract: The present disclosure provides a C-terminal tethered amino acid for modulating the thrombolytic, fibrinolytic and/or anticoagulant properties of a coagulation protein. The present disclosure also provides a coagulation protein having a catalytic site modified, either at the histidine or serine residue, with the C-terminal tethered amino acid as well as therapeutic applications of those modified coagulation proteins.
    Type: Application
    Filed: June 12, 2014
    Publication date: December 18, 2014
    Inventor: Ed Pryzdial
  • Publication number: 20140363419
    Abstract: Short-acting Factor VII peptides are disclosed. A shortened half-life is desirable for treatment of acute bleeding and similar disorders. Modification of the sialylation and/or glycosylation of Factor VII and variants thereof produced peptides useful in treating conditions of acute bleeding.
    Type: Application
    Filed: July 25, 2014
    Publication date: December 11, 2014
    Applicant: BAYER HEALTHCARE LLC
    Inventors: Maxine BAUZON, Terry Hermiston
  • Publication number: 20140356347
    Abstract: The present disclosure provides novel variants of enzymes exhibiting serine protease activity; nucleic acid molecules encoding said proteases, vectors, host cells containing the nucleic acids and methods for preparation and producing such enzymes; compositions and complexes comprising at least one of the proteases; and methods for using such enzymes as a part of an immunoprotease, in particular for the treatment of cancer.
    Type: Application
    Filed: September 21, 2012
    Publication date: December 4, 2014
    Inventors: Stefan Barth, Sonja Schiffer, Grit Hehmann-Titt
  • Publication number: 20140356886
    Abstract: Disclosed are a method for measuring ?G comprising the steps of bringing a sample into contact with a ?G-binding protein 1 and a ?G-binding protein 2, each comprising an amino acid sequence which is identical or substantially identical to an amino acid sequence shown in any one of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, or SEQ ID NO:20, and having the ?-glucan binding activity, to form a complex of the ?G-binding protein 1, ?G in the sample and the ?G-binding protein 2, measuring quantity of the complex, and determining ?G concentration in the sample based on the quantity of the complex; a reagent and a kit for use in said method; a novel ?G-binding protein; a nucleic acid molecule encoding the ?G-binding protein; and a method for producing the aforementioned ?G-binding protein.
    Type: Application
    Filed: August 13, 2014
    Publication date: December 4, 2014
    Inventor: Akito YONEDA
  • Publication number: 20140328818
    Abstract: Gluten-degrading proteases derived from insects, including flour beetles, are isolated, and the purified, and recombinant forms can be used to make gluten-containing food safe for patients suffering from gluten intolerance.
    Type: Application
    Filed: March 30, 2012
    Publication date: November 6, 2014
    Applicant: ALVINE PHARMACEUTICALS, INC.
    Inventor: Pawan Kumar
  • Publication number: 20140329294
    Abstract: The present invention provides culture mediums that are useful for the expression of ADAMTS proteins, such as ADAMTS13. Methods for the expression and purification of ADAMTS proteins are also provided. In some embodiments, the mediums and methods of the invention are useful for the expression of ADAMTS proteins having high specific activities. Also provided are ADAMTS, e.g., ADAMTS13, protein compositions with high specific activities, which are expressed and purified according to the methods provided herein.
    Type: Application
    Filed: May 13, 2014
    Publication date: November 6, 2014
    Applicants: Baxter International Inc., Baxter Healthcare SA
    Inventors: Leopold Grillberger, Alexandra Spenger, Meinhard Hasslacher, Rana Grillberger, Manfred Reiter
  • Patent number: RE46423
    Abstract: Compositions and methods for the treatment of cancer are described, and, more preferably, to the treatment of cancers that do not express, or are otherwise deficient in, argininosuccinate synthetase, with enzymes that deplete L-Arginine in serum. In one embodiment, the present invention contemplates an arginase protein, such as a human Arginase I protein, comprising at least one amino acid substitution and a metal cofactor, said protein comprising an increased catalytic activity when compared with a native human Arginase I.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: June 6, 2017
    Assignee: AERASE, INC.
    Inventors: George Georgiou, Everett Stone